Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects With Pancreatic Cancer

Clinical Application Study of Rejuvenated Tumor-Reactive T Cells in Pancreatic Cancer

A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects with Pancreatic Cancer

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

40

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina
        • Rekrytering
        • Tianjin Medical University Cancer Institute & Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 70 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Informed Consent Form (ICF) .
  • Aged 18 to 70 years (inclusive) at the time of signing the ICF.
  • Cytology or pathology confirmed Patients with pancreatic tumors.

Cohort 1:

  • The subject has undergone radical total resection of the primary tumor with curative intent, as determined by the investigator.
  • Adjuvant chemotherapy completed, as determined by the investigator.

Cohort 2:

  • Disease progression after prior standard systemic antitumor therapy for the current disease stage;
  • Inability to continue standard therapy due to clinically significant and intolerable toxicities, as determined by the investigator, during prior standard treatment;
  • No standard treatment option is currently available, tolerable, and expected to provide clinical benefit for the participant, based on current clinical practice and the investigator's judgment;
  • For locally recurrent disease, radical surgical resection is deemed unsuitable by the investigator.

Cohort 3:

  • Patients receiving standard chemotherapy regimens include, but are not limited to:

    • the oFOLFIRINOX regimen;
    • gemcitabine combined with nab-paclitaxel; or
    • other standard first-line or second-line chemotherapy regimens as determined by the investigator according to local clinical practice guidelines.
  • Patients receiving targeted therapy must meet all the following criteria:

    • Molecular testing confirms a clearly actionable biomarker abnormality (including, but not limited to, BRCA1/2 mutations, KRAS G12C mutation, HER2 alterations, NTRK fusions, or MSI-H/dMMR status);
    • The investigator determines that no contraindications exist for the proposed targeted therapy.
  • ECOG score of 0 ~1 .

  • Expected survival time is more than 12 weeks.

  • Negative blood pregnancy test for females of childbearing potential is required.

Exclusion Criteria:

  • Patients with central nervous system (CNS) metastasis, leptomeningeal disease, or metastatic spinal cord compression; or a history of CNS disorders, including but not limited to epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, etc.
  • History of bone marrow or organ transplantation;
  • History of other primary malignancies;
  • Hepatitis B surface antigen (HBsAg) positivity; With negative HBsAg but positive hepatitis B core antibody (HBcAb) ,and if peripheral blood hepatitis B virus (HBV) DNA positive; Hepatitis C virus (HCV) antibody positive and HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Both Treponema pallidum-specific and non-specific antibody tests are positive.
  • Patients with a known allergy to any component of the study drugs.
  • History of active tuberculosis infection within 1 year prior to screening (subjects with a history of active tuberculosis infection more than 1 year ago are eligible if, in the investigator's judgment, there is no current evidence of active tuberculosis).
  • Concurrent or previous history of interstitial lung disease or interstitial pneumonia; presence of chronic lung disease or other respiratory conditions that significantly impair lung function.
  • Diagnosis of active autoimmune disease or a history of autoimmune disease that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, psoriasis, etc.), or at risk of such conditions.
  • Clinically significant thyroid dysfunction as assessed by the investigator.
  • Any uncontrolled active infection requiring parenteral (IV) antibiotic, antiviral, or antifungal treatment at the time of signing the ICF or within 4 weeks before the first infusion.
  • Clinically significant cardiovascular diseases.
  • Insufficient bone marrow reserve or insufficient organ function.
  • Female subjects who are pregnant or breastfeeding.
  • Administration of attenuated or inactivated vaccines within 28 days before signing the ICF, or planned administration of such vaccines during the screening period.
  • The investigator considers that the subject's complications or other conditions may affect compliance with the protocol or that the subject is unsuitable for participation in this study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Kohort 1

Combination with Adjuvant Chemotherapy

Experimentell: Kohort 2

GKPTZ-01

Experimentell: Kohort 3

Combination with Chemotherapy or Targeted Therapy

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Recurrence-Free Survival
Tidsram: 2 years

6 months RFS(recurrence-free survival) rate(cohort 1)

2 years
Objective response rate
Tidsram: 2 years

Proportion of subjects achieving complete response (CR) and partial response (PR)(cohort 2&3)

2 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Disease Control Rate(DCR)
Tidsram: 2 years

Proportion of subjects achieving best response of CR, PR, or SD treated with GKPTZ-01

2 years
Duration of Response(DOR)
Tidsram: 2 years

Time from first documented evidence of confirmed CR or PR until the first documented evidence of disease progression or death, whichever occurs earlier

2 years
Progression-free Survival(PFS)
Tidsram: 2 years

Time from GKPTZ-01 treatment to disease progression or death

2 years
Overall survival(OS)
Tidsram: 2 years

Time from GKPTZ-01 treatment to death

2 years
Adverse events
Tidsram: 2 years

The incidence and severity of AEs (Adverse Events) and SAEs (Serious Adverse Events).

2 years
Patient Quality of Life
Tidsram: 2 years

EORTC(European Organisation for Research and Treatment of Cancer) QLG (Quality of Life Group)Core Questionnaire (EORTC QLQ-C30)

2 years

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pharmacokinetic
Tidsram: 2 years

Levels of T-cell Receptor copies

2 years
Biomarker
Tidsram: 2 years

Concentration levels of serum cytokines, tumor markers

2 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

2 juni 2026

Primärt slutförande (Beräknad)

1 juli 2028

Avslutad studie (Beräknad)

1 juli 2029

Studieregistreringsdatum

Först inskickad

13 november 2026

Först inskickad som uppfyllde QC-kriterierna

13 november 2026

Första postat (Faktisk)

19 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 november 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera